Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24819894 | 0.90 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL12384822 | 0.85 | EPHX2 (0.44) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL15827186 | 0.85 | EPHX2 (0.44) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL24844030 | 0.85 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL12384823 | 0.83 | SMN1; SMN2 (0.43) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL16886105 | 0.82 | MEN1 (0.53) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL20082923 | 0.82 | MEN1 (0.53) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL12384528 | 0.82 | NAMPT (0.43) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL13741632 | 0.81 | ALDH1A1 (0.41) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL24171560 | 0.81 | ALDH1A1 (0.43) | ALDH1A1LMNAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008424-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2022-01-13 | — | — | US | disclosed |
| US-20200108072-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20180085372-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085372-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170007611-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9409911-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9266893-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-02-23 | — | — | US | disclosed |
| US-9212185-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-9206189-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9193735-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-3998808-A | INSECTICIDES, FUNGICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108072-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885LMNA 3652/4885POLB 1618/4885 |
| US-20220008424-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885LMNA 3652/4885POLB 1618/4885 |
| US-20170007611-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885LMNA 3652/4885POLB 1618/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885LMNA 3652/4885POLB 1618/4885 |
| US-20180085372-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885LMNA 3652/4885POLB 1618/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4461/4885LMNA 4052/4885POLB 1832/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | ALDH1A1 3930/4885LMNA 3672/4885POLB 1631/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | ALDH1A1 3498/4885LMNA 3938/4885POLB 1526/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | ALDH1A1 3500/4885LMNA 3962/4885POLB 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.